Scarica l'app Stockscreener
35.89
0.69%
-0.25
Dopo l'orario di chiusura:
36.42
0.53
+1.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HROW Giù?
Forum
Previsione
Frazionamento azionario
Harrow Inc Borsa (HROW) Ultime notizie
Harrow Inc. Stock Analysis and ForecastMassive wealth growth - PrintWeekIndia
Harrow jumps as Cantor initiates with Bullish view on conservative outlook - MSN
What drives Harrow Inc. stock pricePhenomenal capital appreciation - jammulinksnews.com
What analysts say about Harrow Inc. stockDynamic investment growth - Autocar Professional
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - ETX View
Is Harrow Inc. a good long term investmentOutstanding capital appreciation - jammulinksnews.com
Ladenburg Thalmann & Co. Keeps Their Buy Rating on Harrow Health (HROW) - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - FinancialContent
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio - Eyes On Eyecare
Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook
Harrow's Strategic Positioning in the $9B Ophthalmology Biosimilars Market: Unlocking Value Through Biosimilar Commercialization and Medicare Savings - AInvest
Samsung Bioepis signs U.S. partnership for ophthalmology biosimilar sales - Yonhap News Agency
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc.HROW - cnhinews.com
Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States - TradingView
Harrow Enters into Commercialization Agreement with Samsung Bioe - GuruFocus
Harrow acquires exclusive US rights to Samsung Bioepis eye drugs - Investing.com
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
Harrow Secures Landmark Deal for First FDA-Approved Eye Disease Biosimilars from Samsung Bioepis - Stock Titan
Q2 Earnings Estimate for Harrow Issued By William Blair - Defense World
(HROW) Trading Report - news.stocktradersdaily.com
FY2026 Earnings Estimate for Harrow Issued By William Blair - Defense World
Why Harrow Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser
How Harrow Inc. stock performs during market volatilityTop Performing Stocks - Newser
What makes Harrow Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser
Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar? - Yahoo Finance
HROW’s Stock Performance: A Year of Mixed Fortunes & Market Shifts - investchronicle.com
Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World
Harrow Shares Soar 11.35% on Cantor Fitzgerald's Overweight Rating - AInvest
Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up - Seeking Alpha
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Harrow stock jumps on Cantor Bullish view (HROW:NASDAQ) - Seeking Alpha
Cantor Fitzgerald Initiates Harrow at Overweight With $76 Price Target - MarketScreener
Betting on Ophthalmic Growth Amid Strong Analyst Backing: Harrow, Inc.'s Strategic Play - AInvest
Harrow: Immense Upside Potential (NASDAQ:HROW) - Seeking Alpha
Ongoing Securities Investigation into Harrow, Inc. (HROW)Contact Levi & Korsinsky - ACCESS Newswire
HROW Investor Notice: Levi & Korsinsky Investigates Harrow, Inc. for Securities Law Violations - ACCESS Newswire
William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harrow, Inc. (HROW) And Encourages Stockholders to Reach Out - ACCESS Newswire
4.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):